Skip to main content

Table 1 Patients’ baseline characteristics

From: Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study

  Number (%)
Median Age, years 52.5
ECOG performance status  
0 4 (8.9)
1 36 (80.0)
2 5 (11.1)
Initial stage at diagnosis  
I 6 (14.6)
II 20 (38.8)
III 6 (14.7)
IV 9 (22.0)
Metastatic site  
Locally advanced 4 (8.9)
Regional lymph nodes 7 (15.6)
Distant lymph nodes 14 (31.1)
Lung 18 (40.0)
Liver 17 (37.8)
Bone 25 (55.6)
Skin/Soft tissue 8 (17.8)
Others 13 (28.9)
Number of metastatic sites  
0-1 9 (20.00)
2 11 (24.44)
≥3 25 (55.56)
Previous anthracycline  
Yes 7 (16.28)
No 36 (83.72)
Estrogen receptor  
Positive 26 (57.78)
Negative 16 (35.56)
Unknown 3 (6.67)
Her-2 expressiona  
0, 1+ 30 (66.67)
2+ 4 (8.89)
3+ 5 (11.11)
Unknown 6 (13.33)
  1. Abbreviations: ECOG, Eastern Cooperative Oncology Group
  2. aHer-2 expression was determined by immunohistochemical staining